Literature DB >> 20522584

Worldwide physician education and training in pulmonary hypertension: pulmonary vascular disease: the global perspective.

C Gregory Elliott1, Robyn J Barst, Werner Seeger, Mateo Porres-Aguilar, Lynette M Brown, Roham T Zamanian, Lewis J Rubin.   

Abstract

Pulmonary hypertension (PH) affects > 25 million individuals worldwide and causes premature disability and death for many. The diagnosis and treatment of PH have advanced dramatically through the development of a clearly defined diagnostic classification, an evidence-based treatment algorithm for adults with pulmonary arterial hypertension using life-saving medications, and life-saving surgical procedures. However, worldwide education and training of physicians has lagged behind advances in the management of PH. Expertise in the diagnosis and management of PH is uncommon, even though physicians receive training on PH during their graduate and postgraduate education. Advances in worldwide physician education and training in PH will require substantial organization and work. Organizations working in this field will need to work collaboratively to maximize funding for education and to optimize the achievement of educational goals. Political, economic, and cultural barriers must be identified and overcome as part of any strategic plan. Global education should include training objectives for generalist, non-PH specialist, and PH specialist physicians.

Entities:  

Mesh:

Year:  2010        PMID: 20522584     DOI: 10.1378/chest.09-2816

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  6 in total

Review 1.  Breaking Down the Barriers: Why the Delay in Referral for Pulmonary Arterial Hypertension?

Authors:  Stacy A Mandras; Hector O Ventura; Paul A Corris
Journal:  Ochsner J       Date:  2016

2.  Perceptions of received information, social support, and coping in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.

Authors:  Bodil Ivarsson; Björn Ekmehag; Roger Hesselstrand; Göran Rådegran; Trygve Sjöberg
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2014-10-23

Review 3.  Hallmarks of Pulmonary Hypertension: Mesenchymal and Inflammatory Cell Metabolic Reprogramming.

Authors:  Angelo D'Alessandro; Karim C El Kasmi; Lydie Plecitá-Hlavatá; Petr Ježek; Min Li; Hui Zhang; Sachin A Gupte; Kurt R Stenmark
Journal:  Antioxid Redox Signal       Date:  2017-08-14       Impact factor: 8.401

4.  Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertension.

Authors:  Rajeev Malhotra; Samuel Paskin-Flerlage; Roham T Zamanian; Patrick Zimmerman; Jonathan W Schmidt; Donna Y Deng; Mark Southwood; Robert Spencer; Carol S Lai; William Parker; Richard N Channick; Nicholas W Morrell; C Gregory Elliott; Paul B Yu
Journal:  Pulm Circ       Date:  2013-04       Impact factor: 3.017

5.  Information experiences and needs in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.

Authors:  Bodil Ivarsson; Björn Ekmehag; Trygve Sjöberg
Journal:  Nurs Res Pract       Date:  2014-08-17

Review 6.  Motivations for and Challenges in the Development of Global Medical Curricula: A Scoping Review.

Authors:  Meredith Giuliani; Maria Athina Tina Martimianakis; Michaela Broadhurst; Janet Papadakos; Rouhi Fazelzad; Erik W Driessen; Janneke Frambach
Journal:  Acad Med       Date:  2021-03-01       Impact factor: 7.840

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.